focus -WSS

focus

author：explore 2025-09-27 17:03:13 - browse：42

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： At flashy new research hub, AstraZeneca lays out ambitious growth goals

WSS

Obesity drugs seen as possible treatment for liver disease MASH

PBM reform efforts get punted in Congress

Why palliative psychiatry is worth discussing

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

As a primary care physician, here's how I hope to partner with AI

FDA poised to publish guidelines for clinical trial diversity

knowledge

focus

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Community Health Systems hospitals under DOJ investigation

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why palliative psychiatry is worth discussing

The high cost of giving birth even with insurance

STAT readers on older presidents, polypills, Medicare, and more

explore

UnitedHealth argues against case alleging wrongful AI care denials

Liver decline slowed by off

Digital health: a case of mistaken identity

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Community Health Systems hospitals under DOJ investigation

focus

hotspot

focus

focus